EUROLAB
ph-eur-2420-limit-test-for-heavy-metals-in-impurities
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

Comprehensive Guide to Ph. Eur. 2.4.20: Limit Test for Heavy Metals in Impurities Testing Services Provided by Eurolab

Ph. Eur. 2.4.20: Limit Test for Heavy Metals in Impurities is a laboratory testing service that adheres to the European Pharmacopoeia standards. The European Pharmacopoeia (Ph. Eur.) is a collection of standards and guidelines for pharmaceutical products, including their quality control and testing requirements.

Relevant Standards

  • ISO 17294-1:2004 - Determination of heavy metals in biological samples

  • ASTM E1432-08 - Standard Test Methods for Determining Heavy Metals Content by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

  • EN 15780:2010 - Chemical analysis - Sampling and sample preparation - General guidance on sampling

  • TSE L441:2009 - Foodstuffs, pharmaceuticals, and cosmetics - Methods for the determination of heavy metals content

    • Legal and Regulatory Framework

    The testing service is governed by various laws and regulations, including:

  • The European Unions (EU) Directives on the Safety Assessment of Medicinal Products

  • The EUs Directive 2009/125/EC on ecodesign requirements for products

  • The World Health Organizations (WHO) guidelines for pharmaceutical quality control

    • Standard Development Organizations

    The International Organization for Standardization (ISO), American Society for Testing and Materials (ASTM), European Committee for Electrotechnical Standardization (CENELEC), and Turkish Standards Institution (TSE) are some of the key standard development organizations involved in the development of standards related to Ph. Eur. 2.4.20.

    Standard Evolution and Update

    Standards evolve over time due to advances in technology, changes in regulations, or updated scientific knowledge. Standard development organizations regularly review and update existing standards to ensure they remain relevant and effective.

    Specific Standard Numbers and Scope

    Some of the specific standard numbers related to Ph. Eur. 2.4.20 include:

  • ISO 17294-1:2004 - Determination of heavy metals in biological samples

  • ASTM E1432-08 - Standard Test Methods for Determining Heavy Metals Content by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

  • EN 15780:2010 - Chemical analysis - Sampling and sample preparation - General guidance on sampling

    • Standard Compliance Requirements

    Different industries have varying requirements for standard compliance, including:

  • Pharmaceutical industry: EU GMP guidelines require compliance with Ph. Eur. standards

  • Food industry: EU food safety regulations require compliance with EN 15780:2010

  • Cosmetics industry: EU cosmetics regulation requires compliance with ISO 17294-1:2004

    • Ph. Eur. 2.4.20 is a critical test for ensuring the quality and safety of pharmaceutical products, particularly those containing heavy metals as impurities. The testing service helps to:

  • Ensure compliance with regulatory requirements

  • Detect heavy metal contamination

  • Identify potential health risks associated with heavy metal exposure

  • Support product development and innovation

    • Business and Technical Reasons

    Conducting Ph. Eur. 2.4.20: Limit Test for Heavy Metals in Impurities is necessary due to the following business and technical reasons:

  • Compliance with regulatory requirements

  • Protection of consumer health and safety

  • Detection of heavy metal contamination

  • Support for product development and innovation

    • Consequences of Not Performing This Test

    Failure to conduct Ph. Eur. 2.4.20: Limit Test for Heavy Metals in Impurities can result in:

  • Non-compliance with regulatory requirements

  • Exposure to health risks associated with heavy metal contamination

  • Damage to product reputation and brand value

  • Financial penalties and loss of business

    • Industries and Sectors

    The testing service is required by various industries, including:

  • Pharmaceutical industry: EU GMP guidelines require compliance with Ph. Eur. standards

  • Food industry: EU food safety regulations require compliance with EN 15780:2010

  • Cosmetics industry: EU cosmetics regulation requires compliance with ISO 17294-1:2004

    • Risk Factors and Safety Implications

    Heavy metal contamination can pose significant risks to human health, including:

  • Neurological damage

  • Kidney damage

  • Cancer risk

  • Birth defects

    • Quality Assurance and Quality Control Aspects

    Ph. Eur. 2.4.20: Limit Test for Heavy Metals in Impurities testing involves rigorous quality assurance and quality control measures, including:

  • Calibration of testing equipment

  • Validation of testing methods

  • Regular maintenance of laboratory facilities

  • Strict adherence to standard operating procedures

    • Testing Methodology (ICP-MS)

    The Inductively Coupled Plasma Mass Spectrometry (ICP-MS) technique is used for determining heavy metal content in biological samples. The methodology involves:

  • Sample preparation and digestion

  • Instrument calibration and optimization

  • Data acquisition and analysis

    • Test Report

    A detailed test report is provided, including:

  • Test results

  • Method validation data

  • Calibration certificates

  • Certificate of compliance with regulatory requirements

    • Conclusion

    Ph. Eur. 2.4.20: Limit Test for Heavy Metals in Impurities testing services are essential for ensuring the quality and safety of pharmaceutical products. Compliance with standard requirements is crucial to protect consumer health and prevent regulatory non-compliance.

    ---

    Next section: Testing Methodology (ICP-MS)

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers